These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 27294323)

  • 1. Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation.
    Cha PH; Cho YH; Lee SK; Lee J; Jeong WJ; Moon BS; Yun JH; Yang JS; Choi S; Yoon J; Kim HY; Kim MY; Kaduwal S; Lee W; Min do S; Kim H; Han G; Choi KY
    Nat Chem Biol; 2016 Aug; 12(8):593-600. PubMed ID: 27294323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer.
    Cha PH; Choi KY
    BMB Rep; 2016 Sep; 49(9):455-6. PubMed ID: 27470214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer.
    Cho YH; Cha PH; Kaduwal S; Park JC; Lee SK; Yoon JS; Shin W; Kim H; Ro EJ; Koo KH; Park KS; Han G; Choi KY
    Oncotarget; 2016 Dec; 7(49):81727-81740. PubMed ID: 27835580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
    Lee SK; Hwang JH; Choi KY
    Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule-induced simultaneous destabilization of β-catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells.
    Cho YH; Ro EJ; Yoon JS; Kwak DK; Cho J; Kang DW; Lee HY; Choi KY
    Cell Commun Signal; 2020 Mar; 18(1):38. PubMed ID: 32143715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
    Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
    Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3β.
    Lee SK; Jeong WJ; Cho YH; Cha PH; Yoon JS; Ro EJ; Choi S; Oh JM; Heo Y; Kim H; Min DS; Han G; Lee W; Choi KY
    EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30413483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
    Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
    Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural optimization of novel Ras modulator for treatment of Colorectal cancer by promoting β-catenin and Ras degradation.
    Choi S; Kim H; Ryu WJ; Choi KY; Kim T; Song D; Han G
    Bioorg Chem; 2023 Jan; 130():106234. PubMed ID: 36375353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination.
    Novellasdemunt L; Foglizzo V; Cuadrado L; Antas P; Kucharska A; Encheva V; Snijders AP; Li VSW
    Cell Rep; 2017 Oct; 21(3):612-627. PubMed ID: 29045831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway.
    Jeong WJ; Ro EJ; Choi KY
    NPJ Precis Oncol; 2018; 2(1):5. PubMed ID: 29872723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small molecule compound 759 inhibits the wnt/beta-catenin signaling pathway via increasing the Axin protein stability.
    Sun S; Gong YD; Kang JS; Dong MS; Choi Y
    Med Oncol; 2024 May; 41(6):147. PubMed ID: 38733492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thr160 of Axin1 is critical for the formation and function of the β-catenin destruction complex.
    Koyama-Nasu R; Hayashi T; Nasu-Nishimura Y; Akiyama T; Yamanaka R
    Biochem Biophys Res Commun; 2015 Apr; 459(3):411-5. PubMed ID: 25735981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. H-Ras is degraded by Wnt/beta-catenin signaling via beta-TrCP-mediated polyubiquitylation.
    Kim SE; Yoon JY; Jeong WJ; Jeon SH; Park Y; Yoon JB; Park YN; Kim H; Choi KY
    J Cell Sci; 2009 Mar; 122(Pt 6):842-8. PubMed ID: 19240121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
    Waaler J; Machon O; Tumova L; Dinh H; Korinek V; Wilson SR; Paulsen JE; Pedersen NM; Eide TJ; Machonova O; Gradl D; Voronkov A; von Kries JP; Krauss S
    Cancer Res; 2012 Jun; 72(11):2822-32. PubMed ID: 22440753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
    Lemieux E; Cagnol S; Beaudry K; Carrier J; Rivard N
    Oncogene; 2015 Sep; 34(38):4914-27. PubMed ID: 25500543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/β-catenin signaling.
    Hwang JH; Yoon J; Cho YH; Cha PH; Park JC; Choi KY
    Int J Cancer; 2020 May; 146(10):2877-2890. PubMed ID: 31605540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.